Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ORIC PHARMACEUTICALS, INC.

(ORIC)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
3.500 USD   -3.58%
11/08ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
AQ
11/07ORIC PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
11/07ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2022 11/21/2022 11/22/2022 11/23/2022 11/25/2022 Date
4.45(c) 4(c) 3.66(c) 3.63(c) 3.5(c) Last
318 129 231 409 132 574 46 025 6 371 Volume
+9.88% -10.11% -8.50% -0.82% -3.58% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -89,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,55x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -109 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,56x
Yield 2023 -
Capitalization 139 M 139 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 88
Free-Float 96,7%
More Financials
Company
ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in improving patients' lives by Overcoming Resistance In Cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its... 
More about the company
Ratings of ORIC Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ORIC PHARMACEUTICALS, INC.
11/08ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference
AQ
11/07ORIC PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/07ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/07ORIC Pharmaceuticals Reports Third Quarter 2022áFinancial Results and Operational Updat..
GL
11/03ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple ..
GL
11/03ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple ..
GL
10/07ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
09/08Transcript : ORIC Pharmaceuticals, Inc. Presents at Citi's 17th Annual BioPha..
CI
09/01ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
AQ
08/11Oric Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Operational Updat..
PU
08/11ORIC PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
08/11ORIC Pharmaceuticals Reports Second Quarter 2022áFinancial Results and Operational Upda..
GL
08/11ORIC Pharmaceuticals Reports Second Quarter 2022áFinancial Results and Operational Upda..
GL
08/11ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
CI
06/24ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped fr..
CI
More news
News in other languages on ORIC PHARMACEUTICALS, INC.
11/07ORIC Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les neu..
08/11ORIC Pharmaceuticals, Inc. annonce ses résultats pour le deuxième trimestre et le semes..
05/16L'action d'ORIC Pharmaceuticals grimpe lundi suite à l'acquisition d'actions supplément..
05/16Achats d'initiés : Oric Pharmaceuticals
05/16Le directeur général d'ORIC Pharmaceuticals, Jacob Chacko, acquiert 450 000 actions -- ..
More news
Analyst Recommendations on ORIC PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on ORIC PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Direxion Fallen Knives ETF - USD0.15%-9.78%-NC
IShares Micro-Cap ETF - USD0.04%-0.34%United_States
Invesco Nasdaq Biotechnology ETF - USD0.01%0.38%-United_States
IShares Nasdaq US Biotechnology (D) - USD0.01%-0.21%United_States
IShares Nasdaq US Biotechnology - USD0.01%-0.18%United_States
More ETFs positioned on ORIC PHARMACEUTICALS, INC.
Chart ORIC PHARMACEUTICALS, INC.
Duration : Period :
ORIC Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORIC PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,50 $
Average target price 13,00 $
Spread / Average Target 271%
EPS Revisions
Managers and Directors
Jacob M. Chacko President, Chief Executive Officer & Director
Dominic Piscitelli Chief Financial Officer
Richard A. Heyman Director
Pratik S. Multani Chief Medical Officer
Lori Friedman Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ORIC PHARMACEUTICALS, INC.-76.19%139
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930